Question to the Foreign, Commonwealth & Development Office:

To ask Her Majesty's Government, further to the Written Answer by Baroness Sugg on 30 October (HL9430), what is the breakdown of their financial contribution to the work of the Access to COVID-19 Tools Accelerator (1) by recipient, and (2) by purpose.

The UK has contributed a total of up to £813 million to the Access to COVID-19 Tools Accelerator. This includes up to £250 million of UK Aid to the Coalition for Epidemic Preparedness Innovations (CEPI), an organisation that is supporting the development and manufacturing scale-up of promising COVID-19 vaccines for global use. The UK has committed up to £548 million for the COVAX Advance Market Commitment, which will support access to COVID-19 vaccines for 92 developing countries by contributing to the supply of 1 billion doses in 2021 (subject to vaccines successfully securing stringent regulatory approvals). The UK has also committed £71 million of non-ODA funds to participate in the COVAX Facility for self-financing countries to secure options to vaccines for UK domestic use.

Up to £40 million has been contributed to the COVID-19 Therapeutics Accelerator to support the rapid development of, and access to, treatments for COVID-19. Up to £23 million has been committed to the Foundation for Innovative New Diagnostics (FIND) to drive innovation in the development and delivery of tests to combat major diseases affecting the poorest populations, including COVID-19.